Nereus Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1998-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nereuspharm.com
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-08-16
- Lead Sponsor
- Nereus Pharmaceuticals, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT00630110
- Locations
- 🇦🇷
Hospital Britanico, Capital Federal, Argentina
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇦🇺Mater Adult Hospital, South Brisbane, Queensland, Australia
Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Drug: NPI-2358
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2011-01-10
- Lead Sponsor
- Nereus Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00322608
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States
🇺🇸Institute for Drug Development, San Antonio, Texas, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath